Top

Published in:

01-01-2022 | Acute Myeloid Leukemia | News item

Atypical haemolytic reactions after gemtuzumab ozogamicin

Published in: Reactions Weekly | Issue 1/2022

Excerpt

Five cases of intravascular haemolytic reactions (haemolysis) have been reported internationally after treatment with gemtuzumab ozogamicin [Mylotarg], reports Health Canada. The cases were associated with atypical laboratory reactions including high plasma haemoglobin and normal to high plasma haptoglobin, which could be incorrectly interpreted as in vitro haemolysis and therefore delay diagnosis and treatment of the adverse reactions. …

Health Canada. Atypical hemolytic reactions following exposure to gemtuzumab ozogamicin Health Product InfoWatch : 3-4, Dec 2021. Available from: URL: https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-health-products/medeffect-canada/health-product-infowatch/december-2021/december-2021.pdf

Title: Atypical haemolytic reactions after gemtuzumab ozogamicin
Publication date: 01-01-2022
Publisher: Springer International Publishing
Keywords: Acute Myeloid Leukemia
Gemtuzumab Ozogamicin
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-08343-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Atypical haemolytic reactions after gemtuzumab ozogamicin

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Antineoplastics/folinic-acid

Prednisone

Atosiban/misoprostol

Levodopa/benserazide

Ad26.COV2-S

Immune-globulin/mycophenolate-mofetil